Cu(II)ATSM is under clinical development by Collaborative Medicinal Development and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cu(II)ATSM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cu(II)ATSM is under development for the treatment of Parkinson's disease and amyotrophic lateral sclerosis. It is administered orally. The drug candidate is bis (thiosemicarbazone) derivative. It targets superoxide dismutase (SOD1). It is a copper-containing synthetic small molecule.
Collaborative Medicinal Development overview
Collaborative Medicinal Development (CMD) develops novel therapeutics to treat neurodegenerative diseases and cancer. The company’s CuATSM, a small synthetic molecule that contains copper that eliminates peroxynitrite which is a chemical that inhibits components of the mitochondrial electron transport chain in amyotrophic lateral sclerosis (ALS). It is also developing small molecule ferroptosis inhibitors as first-in-class treatments for neurodegenerative diseases. CMD is advancing its therapeutics to treat Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. The company has operations in in the US and Australia.CMD is headquartered in Mill Valley, California, the US.
For a complete picture of Cu(II)ATSM’s drug-specific PTSR and LoA scores, buy the report here.